StratifiCare is a Singapore-based medtech startup that specializes in developing innovative diagnostic tests that aid healthcare providers to deliver personalized treatment to patients. Their flagship product is a severe dengue prediction test which can be used to tell in advance whether dengue patients will develop severe complications such as internal bleeding and hence require hospitalisation. StratifiCare owns a patent on a panel of biomarkers – blood proteins – whose concentrations change before the patient goes into a severe condition.